类有机物
诱导多能干细胞
药物发现
药品
神经科学
医学
人脑
药物开发
药理学
生物信息学
生物
生物化学
基因
胚胎干细胞
出处
期刊:Methods in molecular biology
日期:2022-01-01
卷期号:: 93-105
被引量:2
标识
DOI:10.1007/978-1-0716-2213-1_10
摘要
The road to discover novel therapeutics for mental and neurological disorders has been severely hampered by the lack of access to relevant testing platforms. Currently, roughly 0.1% of drugs that show promise in preclinical testing make it to Phase I clinical trials, and 90% of those drugs go on to fail FDA approval. One of the reasons responsible for this low success rate is that conventional two-dimensional (2D) cell culture models are not accurate enough predictors of how drugs will work in humans. Three-dimensional (3D) brain organoids differentiated from induced pluripotent stem cells (iPSCs) to resemble specific parts of the human brain, which include architecture composition and physiology, can provide an alternative system that may lead to breakthroughs in key areas of drug testing and toxicological evaluation. Having reliable and scalable iPSC-derived brain organoid models that can much more accurately predict human drug responses will significantly increase success rate in developing treatments for brain-related disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI